Vera Therapeutics, Inc. (NASDAQ:VERA) Receives $78.00 Consensus Target Price from Analysts

Posted by Francis Steltz on Jun 12th, 2026

Vera Therapeutics, Inc. (NASDAQ:VERA – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the twelve ratings firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and ten have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $78.00.

A number of research firms recently weighed in on VERA. Wolfe Research raised shares of Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 target price for the company in a research report on Wednesday, March 11th. TD Cowen reaffirmed a “buy” rating on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. William Blair reaffirmed an “outperform” rating on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vera Therapeutics in a research report on Monday, April 20th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $60.00 target price on shares of Vera Therapeutics in a research report on Tuesday, June 2nd.

Get Our Latest Stock Analysis on Vera Therapeutics

Vera Therapeutics Stock Up 6.4%

Shares of VERA stock opened at $33.65 on Friday. The company has a market capitalization of $2.42 billion, a price-to-earnings ratio of -6.07 and a beta of 0.93. Vera Therapeutics has a 12-month low of $19.07 and a 12-month high of $56.05. The firm has a fifty day moving average of $37.14 and a 200-day moving average of $41.43. The company has a quick ratio of 13.64, a current ratio of 13.64 and a debt-to-equity ratio of 0.15.

Vera Therapeutics (NASDAQ:VERA – Get Free Report) last released its earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.33) by ($0.36). During the same quarter last year, the company earned ($0.81) EPS. As a group, equities research analysts predict that Vera Therapeutics will post -6.23 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Marshall Fordyce sold 22,951 shares of the firm’s stock in a transaction on Tuesday, April 14th. The shares were sold at an average price of $44.05, for a total value of $1,010,991.55. Following the completion of the transaction, the chief executive officer owned 235,244 shares of the company’s stock, valued at approximately $10,362,498.20. This trade represents a 8.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 15.90% of the company’s stock.

Institutional Trading of Vera Therapeutics

Large investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC lifted its stake in Vera Therapeutics by 50.5% in the fourth quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock valued at $36,000 after acquiring an additional 236 shares during the last quarter. Los Angeles Capital Management LLC acquired a new stake in Vera Therapeutics in the fourth quarter valued at $46,000. Aster Capital Management DIFC Ltd acquired a new stake in Vera Therapeutics in the fourth quarter valued at $71,000. Quantbot Technologies LP acquired a new stake in Vera Therapeutics in the second quarter valued at $51,000. Finally, Sandia Investment Management LP acquired a new stake in Vera Therapeutics in the fourth quarter valued at $127,000. Institutional investors and hedge funds own 99.21% of the company’s stock.

Vera Therapeutics Company Profile

(Get Free Report)

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.